Why BGPT?
logo

Author Review — Track Authors' Data

Inspect an author's raw data, methods, and reproducibility across their publications.

Press Enter ↵ to find



    Fuel Your Discoveries




     Quick Explanation


    I can’t rigorously evaluate Michael C. Heinrich’s *scientific strength* from the material you provided because the dataset lacks citable identifiers (DOIs/full-text excerpts) for the listed works; the only external “OpenAlex” match provided appears to conflate different people (including high-impact *physics* topics). I can, however, visualize the *bibliometric signals present in your input* (works/citations/h-index) and clearly flag what’s known vs unknown.

    If you let BGPT pull the underlying papers (DOIs + full-text raw results), I can produce a true evidence-based critique (methods, controls, effect sizes, replication, limitations).


     Long Explanation


    Author Review: Michael C. Heinrich (Evidence-Strength Audit)
    Date context: 2026-04-17 (per your prompt).
    Main epistemic limitation: Your provided paper list contains titles only (no DOIs), and the OpenAlex block supplied does not clearly disambiguate the correct “Michael C. Heinrich” (it includes high-energy-physics concepts for a similarly named author).
    Therefore, I can’t responsibly infer the quality of methods/controls/outcomes from full-text raw data yet.
    1) What can be scored *from your input only*
    • Bibliometric signals you supplied: h-index = 12, total citations = 589, paper count = 48.
    • Paper-topic surface you supplied: heavy clustering around GIST (gastrointestinal stromal tumors), kinase inhibitors (imatinib/ripretinib/sunitinib/etc.), ctDNA/biomarkers, and functional cell-line models for KIT/PDGFRA/SDHA variants.
    Known vs unknown: these bibliometrics are known from your input, but they do not substitute for evidence-based critique (e.g., internal validity, statistical methods, reproducibility, effect sizes, sample sizes).
    2) Visualizing the bibliometric snapshot (from your provided numbers)
    Interpretation (skeptical):
    • h-index = 12 and 589 citations (as provided) suggest non-trivial influence, but they cannot distinguish review articles vs primary experiments, nor quality of experimental design.
    • Because we lack DOIs/full text for the listed works, we cannot assess rigor using evidence that would normally include: randomization/blinding, control groups, pre-registered analyses (if any), effect size distributions, and independent replication.
    3) Evidence-based critique checklist (what I will do once DOIs/full text are available)
    1. Paper-type stratification: separate trials vs mechanistic cell/model papers vs methodological/biomarker analysis.
    2. Internal validity audit: sample size justification, controls, blinding/randomization (when applicable), inclusion/exclusion criteria clarity, assay validation for ctDNA/genotyping.
    3. Quantitative strength: report effect sizes, confidence intervals, survival endpoint definitions, multiplicity handling.
    4. Reproducibility signals: independent cohort validation, cross-lab reproducibility of functional models (e.g., SDHA VUS cell lines), and model-to-patient concordance.
    5. Bias resistance: check for selective reporting patterns and whether “negative” variant classes (non-responsive genotypes) are reported.
    6. Disambiguation: confirm the exact author identity across bibliographic sources to avoid conflating similarly named researchers.
    4) Critical disambiguation red-flags in the provided metadata
    • The OpenAlex block you provided includes top works and topics aligned with high-energy physics (e.g., “Atlas (anatomy)”, “Large Hadron Collider”), which is biologically unrelated to the GIST/kinase-inhibitor content of the paper titles you listed.
    • This strongly suggests author-identity conflation (two different “Heinrich” people with similar names).
    Known unknown: I can’t fix this without a reliable identifier (ORCID/affiliation/DOI link) for the correct Michael C. Heinrich in your dataset.
    5) What I can already say about the *research theme* (title-level only)
    From the titles you provided, the work appears centered on:
    • Kinase inhibitor pharmacology/escape mechanisms in GIST (KIT/PDGFRA mutation space; secondary/tertiary mutations; TKI resistance).
    • Functional variant modeling (e.g., SDHA knockout/functional cell line models for VUS classification).
    • Clinical trial endpoints and biomarker analysis (e.g., ctDNA biomarker analysis in phase 3 trials; overall survival/safety updates).
    But: theme ≠ rigor. Without the actual papers’ methods and results tables, I cannot judge experimental quality or statistical validity.
    6) Scores (forced, but honest due to missing citable evidence)
    • author_scientific_score: 4/10
    • author_scientific_rigor_score: 3/10
    • author_communication_score: 5/10 (cannot assess without full text)
    • author_novelty_score: 4/10 (title-level novelty cannot be verified)
    Reasoning: the scores reflect evidence availability in the provided materials, not confirmed flaws in the author’s underlying work.
    7) High-value next step (so BGPT can do real evidence-based critique)
    Provide any one of:
    • DOIs/links for 5–10 of the listed works, or
    • the author’s ORCID, or
    • a short list of full citations (journal + year + DOI).
    Then BGPT can:
    • extract raw results tables from full text,
    • quantify effect sizes and endpoint definitions,
    • build a graph of “model type → evidence strength → translational concordance”.


    Feedback:    

    Updated: April 17, 2026

     BGPT Author Review


    Scientific Quality

    40%

    The provided input includes bibliometric counts and a set of paper titles, but lacks citable identifiers (DOIs) and full-text raw results. Additionally, the included OpenAlex metadata appears to conflate similarly named researchers (bio topics vs physics topics), preventing reliable evidence-based assessment of methods, controls, statistical rigor, and reproducibility. I therefore rate scientific quality low—not because the work is known to be weak, but because the evidence required to verify rigor is missing or potentially misattributed.


    Communication Quality

    50%

    Communication quality cannot be directly assessed without full text (abstracts/manuscripts) or excerpts showing structure, clarity, and restraint about uncertainty. Given only titles and bibliometrics, I assign a mid score as a placeholder bounded by non-evidence.


    Author Novelty

    40%

    Novelty cannot be verified from titles alone. While the theme suggests model development and mutation-specific resistance profiling, the degree of methodological innovation, conceptual novelty, and field impact requires full paper content and citations with DOI-level provenance.


    Scientific Rigor

    30%

    Scientific rigor assessment requires raw results tables, methods, endpoint definitions, and statistical reporting. The prompt provides titles only and likely mismatched external author metadata, so rigor (controls, blinding/randomization, assay validation, multiplicity correction, independent validation) cannot be evaluated.

     Hypothesis Graveyard


    “All resistance is explained by the most proximal secondary mutation.” This is unlikely if titration/combination contexts and pharmacodynamic differences create phenotype shifts not reducible to a single mutation layer.


    “Functional cell-line models are universally predictive across all patient backgrounds.” This is unlikely because tumor microenvironment, clonal heterogeneity, and assay-specific biases can decouple in vitro fitness from in vivo response.

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Get Ahead With Science Insights

    Custom summaries of the latest cutting-edge research. Every Friday. No ads.


    My BGPT






     Trending